Early Real World Outcomes of the First U.S. Approved Trifocal IOL | ASCRS
Early Real World Outcomes of the First U.S. Approved Trifocal IOL
May 2020
Meeting: 2020 Virtual Annual Meeting
Session: SPS-108 Trifocal IOLs
Authors: Sheri L. Rowen, MD, ABO, Duna Raoof MD
This content is only available for ASCRS Members

This content from the 2020 ASCRS Virtual Annual Meeting is only available to ASCRS members. To log in, click the teal "Login" button in the upper right-hand corner of this page.

To Learn about the outcomes of the first Trifocal lOL by a statistical anaysis of visual outcomes and patient satisfaction. There will be at least 100 patients to include Distance, Intermediate and Near Vision measurements. These patients comprise all appropriate candidates including virgin corneas, post refractive, and mixed & matched IOL's

This is a prospective study to include data from 2 surgeons from a single center for a good sample size. All 1 month and 3 month data will be reported when possible. Techniques will include Manual and Femto assisted cataract surgery, with and without ORA. The visual outcome measurements will include Distance, Intermediate and Near. These will include both monocular and binocular uncorrected and distance corrected vision. A Patient satisfaction survery will be reported as well. Subsets will be broken down to include post refractive surgery, pre treatment for dry eye, and mixed and matched IOL's.

At 1-3 months, 85% of patients had DCVA > or = to 20/25. 72% had 20/20 or better UCIVA. 100% of patients could see J2 with DCNVA. Patient survey revealed 95% had none to mild Glare, with 5% having Moderate glare. 68% reported None to mild halos with 31% moderate. No reports of disabling halos or positive Dysphotopsias were found.79% never use glasses, and 21% use them rarely for fine near tasks. 86% reported an 8-10 level of happiness on a 1-10 scale, and 92% had an 8-10 quality of vision on a 1-10 scale with 10 being the best. 95% would have the same lens again.

In conclusion, the patients who present to any practice whether post lasik or virgin eyes, will have similar results to the FDA study. They have extremely high patient satisfaction and excellent vision. Even with mild to moderate halos, these patients would still have the same lens again and are very happy with their results.
View More Presentations from this Session

This presentation is from the session "SPS-108 Trifocal IOLs" from the 2020 ASCRS Virtual Annual Meeting held on May 16-17, 2020.

We use cookies to measure site performance and improve your experience. By continuing to use this site, you agree to our Privacy Policy and Legal Notice.